Carol Sartorius, PhD

Publications

• Sartorius CA, Harvell DME, Shen T, and Horwitz KB. 2005. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumor xenografts without altering growth. Cancer Res 65(21): 9779-88
• Harvell DME, Richer JK, Allred DC, Sartorius CA, and Horwitz KB. 2006. Estradiol Regulates Different Genes in Human Breast Tumor Xenografts Compared to the Identical Cells in Culture. Endocrinology, 147(2): 700-13
• Tung, L., Abdel-Hafiz, H., Shen, T., Harvell, D. M., Nitao, L. K., Richer, J. K., Sartorius, C. A., Takimoto, G. S., and Horwitz, K. B. Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol, 20: 2656-2670, 2006.
• Harrell, J. C., Dye, W. W., Allred, D. C., Jedlicka, P., Spoelstra, N. S., Sartorius, C. A., and Horwitz, K. B. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res, 66: 9308-9315, 2006.
• Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA and Horwitz KB. 2007. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res, 67(21): 10582-91.
• Harrell JC, Dye WW, Harvell DM, Sartorius CA and Horwitz KB. 2008. Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clin Exp Metastasis, 25(1): 81-8.
• Horwitz KB, Dye WW, Harrell JC, Kabos P and Sartorius CA. 2008. Rare steroid receptor negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA, in press.
• Horwitz KB and Sartorius CA. 2008. Progestins in hormone replacement therapies reactivate cancer stem cells in women with pre-existing breast cancers: a hypothesis. J Clin Endocrinol Metab (Commentary), 93(9):3295-8. PMID: 18647813
• Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb;4(1):36-49. PubMed PMID: 23184698
• Reid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DV. Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery. Curr Chem Genomics Transl Med. 2014;8(Suppl 1):27-35. PubMed PMID: 24596682
• Progestin gene regulation in dual PR/AR positive breast tumors Jessica Finlay-Schultz1, Peter Hendricks1, Rachel B. Rosen1, Kale Flory2, Anthony Elias2, Britta M. Jacobsen3, Peter Kabos2, and Carol A. Sartorius1 1Dept of Pathology, 2Division of Medical Oncology, 3Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO
• Retinoic Acid Receptor (RARa)-Progesterone Receptor (PR) crosstalk in controlling the luminal breast cancer stem cell population Purvi R. Patel*, Sunshine D. Axlund, Jerome Schaack, Daniel V. LaBarbera, and Carol A. Sartorius University of Colorado Anschutz Medical Campus, Aurora, CO
• Harrell JC, Dye WW, Harvell DME, Pinto M, Sartorius CA, and Horwitz KB. Breast cancer lymphatic dissemination - influence of estrogen and progesterone. Department of Defense Breast Cancer Research Program Era of Hope Meeting, Baltimore MD, June 2008
• Progesterone downregulation of miR-141 facilitates expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a Jessica Finlay-Schultz1, Diana M. Cittelly1, Peter Hendricks1, Purvi Patel1, Peter Kabos2, Britta M. Jacobsen1, Jennifer K. Richer1, and Carol A. Sartorius1 1Department of Pathology, and 2Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
• Reid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DV. Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery. Curr Chem Genomics Transl Med. 2014;8(Suppl 1):27-35. PubMed PMID: 24596682
• Kabos P, Dye WW, Elias A, Horwitz KB and Sartorius CA. The chemoresistant population of luminal subtype human breast cancer cells expresses a basal phenotype. 31st San Antonio Breast Cancer Symposia, San Antonio TX, December 2008.
• Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2014 Sep 22;0. [Epub ahead of print] PubMed PMID: 25241899
• Sartorius CA, Hanna C, Cruz H, Serkova NJ, Kabos P, Borges VF, Gril B, Steeg PS, and Cittelly DM. Estrogens promote brain metastatic colonization of ER negative breast cancer cells via paracrine action through astrocytes. pending submission.
• Haughian JM, Horwitz KB, and Sartorius CA. Progestin-dependent Conversion of ER+PR+ CK5- Luminal to ER-PR-CK5+ Basal-like Breast Cancer Stem Cells. American Association for Cancer Research, Denver CO, April 2009.
• Kabos P, Dye WW, Elias A, Horwitz KB, and Sartorius CA. Rare ER–/CK5+ cells in luminal type human breast cancers are resistant to hormone therapy and chemotherapy and repopulate ER+ tumors. American Association for Cancer Research, Denver CO, April 2009.
• Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, and Sartorius CA. Cytokeratin 5 positive cells represent a therapy resistant subpopulation in epithelial ovarian cancer. pending submission.
• Heather Brechbuhl, Jessica Finlay-Schultz, Chunling Li, Sharon Sams, Aik C Tan, Manoj M Pillai, Diana M. Cittelly, Anthony D Elias, Carol A Sartorius, and Peter Kabos. Stromal subtypes defined by CD146 expression direct epithelial heterogeneity of estrogen receptor expression and control the response to chemotherapy in breast cancer. pending submission.
• Harrell JC, Dye WW, Harvell DM, Sartorius CA and Horwitz KB. 2008. Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clin Exp Metastasis, 25(1): 81-8. PMID: 17932773
• Horwitz KB, Dye WW, Harrell JC, Kabos P and Sartorius CA. 2008. Rare steroid receptor negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA, 105(15): 5774-9. PMID: 18391223
• Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 May;14(5):1117-29. PubMed PMID: 25758253
• Finlay-Schultz J, Sartorius CA. Steroid Hormones, Steroid Receptors, and Breast Cancer Stem Cells. J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):39-50. PubMed PMID: 26265122
• Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2015 Sep 28. [Epub ahead of print] PubMed PMID: 26411365
• Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2015 Nov;25(9):1565-73. PubMed PMID: 26495758
• Kabos P, Haughian JM, Wang X, Dye WW, Elias A, Horwitz KB, and Sartorius CA. Cytokeratin 5 positive cells represent a drug resistant subpopulation in luminal breast cancers. Mol Canc Ther, submitted.
• Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nat Commun. 2015 Dec 21;6:10077. PubMed PMID: 26687066
• Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius C, and Spillman MA. Progestin Treatment Decreases CD133+ Cancer Stem Cell Populations in Endometrial Cancer. Gyn Oncol, in press.
• Spillmann MA, Jacobsen BM, Manning N, Sartorius CA, and Horwitz KB. TISSUE SPECIFIC PATHWAYS FOR ESTROGEN REGULATION OF OVARIAN CANCER GROWTH AND METASTASIS, Nature Medicine, submitted.
• Kabos P, Haughian JM, Wang X, Dye WW, Elias A, Horwitz KB, and Sartorius CA. Cytokeratin 5 positive cells represent a drug resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat. 2010 Jul 28. [Epub ahead of print] PMID: 20665103.
• Cittelly D, Ricker JK and Sartorius CA. Ovarian steroid hormones: what’s hot in the stem cell pool? Breast Cancer Res, 2010;12(4):309. PMID: 20825628
• Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016 Dec;35(4):547-573. PubMed PMID: 28025748
• Wellberg EA, Johnson S, Finlay-Schultz J, Lewis AS, Terrell KL, Sartorius CA, Abel ED, Muller WJ, Anderson SM. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis. Breast Cancer Res. 2016 Dec 20;18(1):131. PubMed PMID: 27998284
• Axlund SD and Sartorius CA. Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol, submitted.
• Axlund SD, Sartorius CA. Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol. Sept 16 2011. PMID: 21945473
• Hanna C, Kwok L, Finlay-Schultz J, Sartorius CA, Cittelly DM. Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies. J Vis Exp. 2016 Nov 30;(117). PubMed PMID: 27929464
• Matthews SB, Sartorius CA. Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts. Horm Cancer. 2016 Oct 28. [Epub ahead of print] PubMed PMID: 27796944
• Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius, C. A., Tan AC, Heikkila P, Perou CM, Horwitz KB. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci USA 2012 Feb 21;109(8):2742-7. Epub 2011 Oct 3.
• Brechbuhl HM, Finlay-Schultz J, Yamamoto T, Gillen A, Cittelly DM, Tan AC, Sams SB, Pillai M, Elias A, Robinson WA, Sartorius CA, Kabos P. Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin Cancer Res. 2016 Oct 4. [Epub ahead of print] PubMed PMID: 27702820
• Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA and LaBarbera DV. A high content assay to identify small molecule modulators of a cancer stem cell population in luminal breast cancer. J Mol Screening, 2012 Oct;17(9):1211-20. Epub 2012 Jun 29. PMID: 22751729
• D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Mol Cancer Res. 2016 Nov;14(11):1054-1067. PubMed PMID: 27565181
• Iwanaga R, Wang CA, Micalizzi2 DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP and Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of ERK and TGF-ß signaling pathways. Breast Cancer Res, 2012 Jul 5;14(4):R100. PMID:22765220
• Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA. Progestin treatment decreases CD133 cancer stem cell populations in endometrial cancer. Gynecol Oncol. 2016 Mar;140(3):518-26. PubMed PMID: 26731726
• Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra N, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA and Richer JK. Progestin-mediated suppression of miR-29 potentiates de-dedifferentiation of breast cancer cells through upregulation of KLF4. Oncogene, 2012 Jul 2 [Epub ahead of print] PMID: 22751119.
• Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Edgerton SM, Harrell JC, Elias A and Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen dependent gene signatures. Breast Cancer Res Treat, 2012 Sept;135(2):415-32. Epub 2012 Jul 24. PMID: 22821401
• Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2016 Jun 2;35(22):2881-92. PubMed PMID: 26411365
• Gracanin A, van Wolferen ME, Sartorius CA, Brenkman AB, Schoonen WG, Mol JA. Canid Progesterone Receptors Lack Activation Function 3 Domain-Dependent Activity. Endocrinology, 2012 Dec;153(12):6104-13. PMID:23041671
• Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Front Oncol. 2017;7:94. PubMed PMID: 28555173
• Axlund SD, Yoo B, Kabos P, Rosen RB, Schaack J, LaBarbera D and Sartorius CA. Progesterone-inducible cytokeratin 5 positive cells in luminal breast cancer exhibit progenitor properties. Hormones and Cancer, 2013 Feb;4(1):36-49]. PMID:23184698
• Fettig LM, McGinn O, Finlay-Schultz J, LaBarbera DV, Nordeen SK, Sartorius CA. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells. Oncogene. 2017 Nov 2;36(44):6074-6084. PubMed PMID: 28692043
• Sartorius CA, Finlay-Schultz J, Li C, Rosen RB, Hendricks P, Wisell J, Finlayson C, Elias A and Kabos P. Progestins exert divergent growth effects and regulate tumor-unique gene cohorts in patient-derived breast cancer xenografts. 35th San Antonio Breast Cancer Symposia, San Antonio, TX, December 2012, Poster
• Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Cancer Res. 2017 Sep 15;77(18):4934-4946. PubMed PMID: 28729413
• Riemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JR. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2019 Feb 28;47(4):e20. PubMed PMID: 30496484
• Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 Jul 25;3(14). [Epub ahead of print] PubMed PMID: 30046001
• Alzubi MA, Turner TH, Olex AL, Sohal SS, Tobin NP, Recio SG, Bergh J, Hatschek T, Parker JS, Sartorius CA, Perou CM, Dozmorov MG, Harrell JC. Separation of breast cancer and organ microenvironment transcriptomes in metastases. Breast Cancer Res. 2019 Mar 6;21(1):36. PubMed PMID: 30841919
• Fettig LM, Sartorius CA. Phospho-PR Isoforms and Cancer Stem Cells: What Does the FOXO1 Say?. Endocrinology. 2019 May 1;160(5):1067-1068. PubMed PMID: 30901022
• McGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J and Sartorius CA.Cytokeratin 5 alters ß-catenin dynamics in breast cancer cells. Oncogene, accepted Dec 2019, in press
• Brechbuhl H, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K and Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight, accepted Jan 2020, in press
• Riemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JR. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2018 Nov 29. [Epub ahead of print] PubMed PMID: 30496484
• Sequeira GR, Sahores A, Dalotto-Moreno T, Perrotta RM, Pataccini G, Vanzulli SI, Polo ML, Radisky DC, Sartorius CA, Novaro V, Lamb CA, Rabinovich GA, Salatino M, Lanari C. Enhanced antitumor immunity via endocrine therapy prevents mammary tumor relapse and increases immune checkpoint blockade sensitivity. Cancer Res. 2020 Dec 2. [Epub ahead of print] PubMed PMID: 33268529
• Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor breast cancer. Br J Cancer. 2021 Jan;124(1):217-227. PubMed PMID: 33144693
• Sartorius CA, Horwitz KB. Response to: Progesterone and breast cancer pathogenesis. J Mol Endocrinol. 2020 Oct 1. [Epub ahead of print] PubMed PMID: 33112797
• Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2020 Oct 23. [Epub ahead of print] PubMed PMID: 33097494
• Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 Oct;59(10):1129-1139. PubMed PMID: 32822091
• Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CA. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020 Jun 23;22(1):68. PubMed PMID: 32576280
• Horwitz KB, Sartorius CA. 90 YEARS OF PROGESTERONE: Progesterone and progesterone receptors in breast cancer: past, present, future. J Mol Endocrinol. 2020 Jul;65(1):T49-T63. PubMed PMID: 32485679
• Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020 Feb 27;5(4). PubMed PMID: 32045383
• McGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J, Sartorius CA. Cytokeratin 5 alters ß-catenin dynamics in breast cancer cells. Oncogene. 2020 Mar;39(12):2478-2492. PubMed PMID: 31988452
• Hickey TE, Selth LA, Chia KM, Milioli HH, Roden D, Laven-Law D, Jindal S, Hui M, Ebrahimie E, Birrell SN, Stelloo S, Caldon CE, Finlay-Schultz J, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. The androgen receptor is a tumor suppressor in estrogen receptor positive breast cancer. Nature Medicine, in press.
• Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 Jan 15;27(2):585-597. PubMed PMID: 33097494
• Horwitz KB, Sartorius CA. Response to: Progesterone and breast cancer pathogenesis. J Mol Endocrinol. 2021 Jan;66(1):L1-L2. PubMed PMID: 33112797
• Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor breast cancer. Br J Cancer. 2021 Jan;124(1):217-227. PubMed PMID: 33144693
• Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, Birrell SN, Stelloo S, Iggo R, Alexandrou S, Caldon CE, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021 Feb;27(2):310-320. PubMed PMID: 33462444
• Sequeira GR, Sahores A, Dalotto-Moreno T, Perrotta RM, Pataccini G, Vanzulli SI, Polo ML, Radisky DC, Sartorius CA, Novaro V, Lamb CA, Rabinovich GA, Salatino M, Lanari C. Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity. Cancer Res. 2021 Mar 1;81(5):1375-1387. PubMed PMID: 33268529
• Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2021 Dec 2. [Epub ahead of print] PubMed PMID: 34856027
• Ward AV, Anderson SM, Sartorius CA. Advances in Analyzing the Breast Cancer Lipidome and Its Relevance to Disease Progression and Treatment. J Mammary Gland Biol Neoplasia. 2021 Dec 16. [Epub ahead of print] PubMed PMID: 34914014
• Abascal MF, Elía A, Alvarez M, Pataccini G, Sequeira G, Riggio M, Figueroa V, Lamb CA, Rojas PA, Spengler E, Martínez-Vazquez P, Burruchaga J, Liguori M, Sahores A, Wargon V, Molinolo A, Hewitt S, Lombes M, Sartorius C, Vanzulli SI, Giulianelli S, Lanari C. Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1. Int J Cancer. 2021 Dec 22. [Epub ahead of print] PubMed PMID: 34935137
• Semina SE, Alejo LH, Chopra S, Kansara NS, Kastrati I, Sartorius CA, Frasor J. Identification of a novel ER-NF?B-driven stem-like cell population associated with relapse of ER ?breast tumors. Breast Cancer Res. 2022 Dec 8;24(1):88. PubMed PMID: 36482488
• Rao S, Han AL, Zukowski A, Kopin E, Sartorius CA, Kabos P, Ramachandran S. Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer. Sci Adv. 2022 Aug 26;8(34):eabm4358. PubMed PMID: 36001652
• McGinn O, Riley D, Finlay-Schultz J, Paul KV, Kabos P, Sartorius CA. Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer. Mol Cancer Res. 2022 Sep 2;20(9):1443-1455. PubMed PMID: 35639459
• Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun. 2022 Apr 19;13(1):2011. PubMed PMID: 35440136
• Ward AV, Matthews SB, Fettig LM, Riley D, Finlay-Schultz J, Paul KV, Jackman M, Kabos P, MacLean PS, Sartorius CA. Estrogens and Progestins Cooperatively Shift Breast Cancer Cell Metabolism. Cancers (Basel). 2022 Mar 31;14(7). PubMed PMID: 35406548
• Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2022 Mar;61(3):359-371. PubMed PMID: 34856027
• Abascal MF, Elia A, Alvarez M, Pataccini G, Sequeira G, Riggio M, Figueroa V, Lamb CA, Rojas PA, Spengler E, Martínez-Vazquez P, Burruchaga J, Liguori M, Sahores A, Wargon V, Molinolo A, Hewitt S, Lombes M, Sartorius C, Vanzulli SI, Giulianelli S, Lanari C. Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1. Int J Cancer. 2022 May 1;150(9):1481-1496. PubMed PMID: 34935137
• Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, Walker JK, Steinauer N, Zhang J, Coons LA, Korach KS, Cain DW, Hollenberg AN, Webb P, Forrest D, Jetten AM, Edwards DP, Grimm SL, Hartig S, Lange CA, Richer JK, Sartorius CA, Tetel M, Billon C, Elgendy B, Hegazy L, Griffett K, Peinetti N, Burnstein KL, Hughes TS, Sitaula S, Stayrook KR, Culver A, Murray MH, Finck BN, Cidlowski JA. International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023. Pharmacol Rev. 2023 Nov;75(6):1233-1318. PubMed PMID: 37586884
• Zboril EK, Grible JM, Boyd DC, Hairr NS, Leftwich TJ, Esquivel MF, Duong AK, Turner SA, Ferreira-Gonzalez A, Olex AL, Sartorius CA, Dozmorov MG, Harrell JC. Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER Breast Cancer. Cancers (Basel). 2023 Jun 14;15(12). PubMed PMID: 37370789
• Mapping Transcription Factor-Nucleosome Dynamics from Plasma cfDNA Satyanarayan Rao, Amy L. Han, Alexis Zukowski, Etana Kopin, Carol A. Sartorius, Peter Kabos, Srinivas Ramachandran doi: https://doi.org/10.1101/2021.04.14.439883